Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 3/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.30 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK7 | P50613 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
| ▸ | CCNH | P51946 | 1/20 | 0.30 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL567231 | 0.89 | DGAT1 (0.32) | JAK2JAK1KDM1ADGAT1BRD4 | |
| SCHEMBL10099165 | 0.84 | BRD4 (0.33) | JAK2JAK1DGAT1JAK3BRD4 | |
| SCHEMBL565566 | 0.83 | GRM2 (0.35) | JAK2JAK1DGAT1JAK3 | |
| SCHEMBL566635 | 0.83 | GRM2 (0.35) | JAK2JAK1DGAT1JAK3 | |
| SCHEMBL10099319 | 0.81 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL10099290 | 0.81 | JAK2 (0.33) | JAK2JAK1DGAT1JAK3BRD4 | |
| SCHEMBL10099143 | 0.79 | SCN9A (0.40) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL630837 | 0.79 | MTOR (0.33) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL10099291 | 0.78 | DGAT1 (0.32) | DGAT1BRD4CREBBP | |
| SCHEMBL10099139 | 0.78 | SCN9A (0.42) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885KDM1A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.